COL1A1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Cancer

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2021 Apr 14

PMID 33850663

Citations 30

Authors

Qishun Geng

Zhibo Shen

Lifeng Li

Jie Zhao

Affiliations

Soon will be listed here.

Abstract

Objective: Lung cancer (LC) is one of the top ten malignant tumors and the first leading cause of cancer-related death among both men and women worldwide. It is imperative to identify immune-related biomarkers for early LC diagnosis and treatment.

Methods: Three Gene Expression Omnibus (GEO) datasets were selected to acquire the differentially expressed genes(DEGs) between LC and normal lung samples through GEO2R tools of NCBI. To identify hub genes, the DEGs were performed functional enrichment analysis, the protein-protein interaction (PPI) network construction, and Lasso regression. Then, a nomogram was constructed to predict the prognosis of patients with carcinoma based on hub genes. We further evaluated the influence of COL1A1 on clinical prognosis using GSE3141, GSE31210, and TCGA database. Also, the correlations between COL1A1 and cancer immune infiltrates and the B7-CD28 family was investigated via TIMER and GEPIA. Further analysis of immunohistochemistry shown that the COL1A1 expression level is positively correlated with CD276 expression level.

Results: By difference analysis, there were 340 DEGs between LC and normal lung samples. Then, we picked out seven hub genes, which were identified as components of the risk signature to divide LC into low and high-risk groups. Among them, the expression of COL1A1 is highly correlated with overall survival(OS) and progression-free survival (PFS) ( < 0.05). Importantly, there is a moderate to strong positive relationships between COL1A1 expression level and infiltration level of CD4+ T cells, Macrophage, Neutrophil, and Dendritic cell, as well as CD276 expression level.

Conclusion: These findings suggest that COL1A1 is correlated with prognosis and immune infiltrating levels, including CD4+ T cells, Macrophage, Neutrophil, and Dendritic cell, as well as CD276 expression level, indicating COL1A1 can be a potential immunity-related biomarker and therapeutic target in LC.

Citing Articles

Col1A1 as a new decoder of clinical features and immune microenvironment in ovarian cancer.

Xiao X, Long F, Yu S, Wu W, Nie D, Ren X Front Immunol. 2025; 15():1496090.

PMID: 39845977 PMC: 11750837. DOI: 10.3389/fimmu.2024.1496090.

Biological implications of decoding the extracellular matrix of vulva cancer.

Islam M, Debnath K, Moniruzzaman R, Okuyama K, Islam S, Dongre H Oncol Rep. 2024; 53(2).

PMID: 39670289 PMC: 11652961. DOI: 10.3892/or.2024.8852.

stMMR: accurate and robust spatial domain identification from spatially resolved transcriptomics with multimodal feature representation.

Zhang D, Yu N, Yuan Z, Li W, Sun X, Zou Q Gigascience. 2024; 13.

PMID: 39607984 PMC: 11604062. DOI: 10.1093/gigascience/giae089.

Mesothelioma survival prediction based on a six-gene transcriptomic signature.

Behrouzfar K, Mutsaers S, Chin W, Patrick K, Ng I, Pixley F iScience. 2024; 27(10):111011.

PMID: 39474071 PMC: 11519557. DOI: 10.1016/j.isci.2024.111011.

Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma.

Su Y, Huo T, Wang Y, Li J Clin Transl Oncol. 2024; .

PMID: 39292390 DOI: 10.1007/s12094-024-03703-1.

References

Chakravarthy D, Munoz A, Su A, Hwang R, Keppler B, Chan D . Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1. Cancer Lett. 2018; 419:103-115. PMC: 5858579. DOI: 10.1016/j.canlet.2018.01.057. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Tanaka A, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Cell Res. 2016; 27(1):109-118. PMC: 5223231. DOI: 10.1038/cr.2016.151. View

Li F, Teng H, Liu M, Liu B, Zhang D, Xu Z . Prognostic Value of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer. Front Oncol. 2020; 10:1302. PMC: 7399341. DOI: 10.3389/fonc.2020.01302. View

ODonnell J, Teng M, Smyth M . Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2018; 16(3):151-167. DOI: 10.1038/s41571-018-0142-8. View

Oleksiewicz U, Liloglou T, Tasopoulou K, Daskoulidou N, Gosney J, Field J . COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer. J Cancer Res Clin Oncol. 2017; 143(7):1133-1141. PMC: 5486546. DOI: 10.1007/s00432-017-2381-y. View

Szklarczyk D, Gable A, Lyon D, Junge A, Wyder S, Huerta-Cepas J . STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018; 47(D1):D607-D613. PMC: 6323986. DOI: 10.1093/nar/gky1131. View

Kabbout M, Garcia M, Fujimoto J, Liu D, Woods D, Chow C . ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013; 19(13):3383-95. PMC: 3846434. DOI: 10.1158/1078-0432.CCR-13-0341. View

Janakiram M, Shah U, Liu W, Zhao A, Schoenberg M, Zang X . The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev. 2017; 276(1):26-39. PMC: 5338461. DOI: 10.1111/imr.12521. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Marini J, Forlino A, Bachinger H, Bishop N, Byers P, De Paepe A . Osteogenesis imperfecta. Nat Rev Dis Primers. 2017; 3:17052. DOI: 10.1038/nrdp.2017.52. View

12.

Lu P, Weaver V, Werb Z . The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196(4):395-406. PMC: 3283993. DOI: 10.1083/jcb.201102147. View

13.

Leon L, Gautier M, Allan R, Ilie M, Nottet N, Pons N . The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene. 2019; 38(46):7146-7165. DOI: 10.1038/s41388-019-0935-y. View

14.

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

15.

Smoot M, Ono K, Ruscheinski J, Wang P, Ideker T . Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2010; 27(3):431-2. PMC: 3031041. DOI: 10.1093/bioinformatics/btq675. View

16.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

17.

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

18.

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A . ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25(8):1091-3. PMC: 2666812. DOI: 10.1093/bioinformatics/btp101. View

19.

Schildberg F, Klein S, Freeman G, Sharpe A . Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016; 44(5):955-72. PMC: 4905708. DOI: 10.1016/j.immuni.2016.05.002. View

20.

Wu W, Yang Z, Long F, Luo L, Deng Q, Wu J . COL1A1 and MZB1 as the hub genes influenced the proliferation, invasion, migration and apoptosis of rectum adenocarcinoma cells by weighted correlation network analysis. Bioorg Chem. 2020; 95:103457. DOI: 10.1016/j.bioorg.2019.103457. View